Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cancer communications

- PMLiVE

Pfizer launches personalised lung cancer drug Xalkori in UK

Becomes first treatment on the market for ALK-positive NSCLC

- PMLiVE

FDA approves Exelixis’ Cometriq for rare thyroid cancer

Genomics-based discovery company also submits the drug to EU regulators

Charles Morris appointed chief development officer at ImmunoGen

Previously worked in oncology for Allos, Cephalon and AstraZeneca

Eisai: Bucking the trend with R&D growth

PME’s emerging companies series continues with a firm that’s committed to research as it expands its commercial position

- PMLiVE

Astellas seeks FDA approval for personalised Tarceva in lung cancer

Application supported by Roche's EGFR companion diagnostic test

- PMLiVE

Burson-Marsteller appoint new EMEA health MD

Kate Hawker joins the agency from InforMed

- PMLiVE

Roche’s Avastin cuts progression of aggressive brain cancer

Supports potential new indication for oncology medicine

Sanofi reception

Sanofi’s Lyxumia and Zaltrap backed for European approval

Company on course to expand its diabetes and cancer portfolio

- PMLiVE

WHO launches framework to monitor non-communicable diseases

Will measure success of efforts to reduce rates of cancer, diabetes, lung conditions and heart disease

- PMLiVE

Havas Health launches new agency group, Havas Lynx

Combines Havas Life 4D and Creative Lynx into a new, single entity

- PMLiVE

New hope for castration-resistant prostate cancer

An unprecedented number of therapies have reached late-stage clinical trials or been approved over recent years targeting this disease with an unmet medical need

- PMLiVE

NICE rejects Pierre Fabre’s bladder cancer drug Javlor

Says drug received final draft 'no' because pharma company failed to prove efficacy

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links